Bio Essence

Bio Essence FCF Growth

The Year-over-Year Free Cash Flow Growth of Bio Essence (BIOE) as of Oct 28, 2026 is 151.62 %. In the previous year, Year-over-Year Free Cash Flow Growth was 160.61 % — a change of -5.60% (lower).

FCF Growth

151.62 %

YoY

-5.60%

Last updated:

Year-over-Year Free Cash Flow Growth of Bio Essence is 2025 151.62 % . Year-over-Year Free Cash Flow Growth of Bio Essence was 2024 160.61 % . It decreases by -5.60% lower compared to the previous year.

The Bio Essence FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2018
57.76 USD
Jan 1, 2019
0.34 USD
Jan 1, 2020
19.95 USD
Jan 1, 2021
-91.00 USD
Jan 1, 2022
46.07 USD
Jan 1, 2023
-35.01 USD
Jan 1, 2024
160.61 USD
Jan 1, 2025
151.62 USD
The Bio Essence FCF Growth history
YEARFCF GrowthYoY
151.62 %-5.60%
160.61 %-558.72%
-35.01 %-176.00%
46.07 %-150.63%
-91.00 %-556.12%
19.95 %+5,748.17%
0.34 %-99.41%
57.76 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Essence Stock analysis

What does Bio Essence do? Bio Essence Corp. generates revenue through its three subsidiaries: Bio Essence Pharmaceutical (BEP), which operates as a health supplement original equipment manufacturer (OEM) service provider; Bio Essence Herbal Essentials (BEH), which targets healthcare practitioners with herbal products including granules, capsules, pills, and tablets, and offers special formulation services; and McBE Pharma (McBE), which develops, manufactures, and sells prescription drugs. The company's products are sold directly to healthcare practitioners such as dietitians and nutraceutical practitioners, who then recommend them to their patients. BEH specifically serves practitioners in the integrative healthcare market, providing both standard and custom-formulated herbal supplements. BEP functions as an OEM for health supplement manufacturers, producing private-label products under other brands. McBE Pharma focuses on prescription drugs, targeting healthcare providers for direct sales. The firm's direct connections with practitioners enable it to reach end consumers through professional recommendations rather than retail channels. Bio Essence Herbal Essentials Inc. (BEH) emphasizes its role in connecting practitioners with patients through tailored herbal supplement solutions. The company's revenue streams are derived from the sale of herbal health supplements, vitamin nutritional supplements, and prescription drugs. BEH's target segment includes practitioners who specialize in integrative healthcare, such as dietitians and nutraceutical practitioners, who use the company's products to support patient care. McBE Pharma's segment consists of healthcare providers seeking prescription drug solutions for their patients. BEP serves as a manufacturing partner for other supplement brands, supplying OEM services. Bio Essence is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Essence stock

Year-over-Year Free Cash Flow Growth of Bio Essence is 151.62 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Bio Essence since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Bio Essence historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Bio Essence

All Key Metrics — Bio Essence